表紙:細胞治療薬製造の市場予測・競合動向・成長機会 (~2026年):治療法・細胞区分・運用規模・調達・用途・エンドユーザー・地域別
市場調査レポート
商品コード
1025672

細胞治療薬製造の市場予測・競合動向・成長機会 (~2026年):治療法・細胞区分・運用規模・調達・用途・エンドユーザー・地域別

Global Cell Therapy Manufacturing Market, By Therapy, By Source of Cell, By Scale of Operation, By Source, By Application, By End User, By Region, Competition Forecast & Opportunities, 2026

出版日: | 発行: TechSci Research | ページ情報: 英文 119 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.75円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

細胞治療薬製造の市場予測・競合動向・成長機会 (~2026年):治療法・細胞区分・運用規模・調達・用途・エンドユーザー・地域別
出版日: 2021年09月01日
発行: TechSci Research
ページ情報: 英文 119 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の細胞治療薬製造の市場は予測期間中大幅なCAGRで成長すると予測されています。

世界のバイオ医薬品産業が急速に成長しており、同市場の成長を推進しています。また、先進的な治療法の開発や、いくつかの生命を脅かす疾患の変化も今後5年間の市場成長を牽引する見通しです。さらに、新型コロナウイルス感染症 (COVID-19) の世界的流行も市場成長に重要な役割を果たしています。

当レポートでは、世界の細胞治療薬製造の市場を調査し、市場の定義と概要、COVID-19およびその他の市場影響因子の分析、顧客の声の分析、特許動向、臨床試験の動向、市場規模の推移・予測、治療法・細胞区分・運用規模・調達・用途・エンドユーザー別の内訳、地域・主要国別の詳細分析、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 製品の概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19の影響

第5章 顧客の声

第6章 世界市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • 治療法別
      • T細胞療法
      • 樹状細胞療法
      • 腫瘍細胞療法
      • 幹細胞療法
    • 細胞区分別
      • 自家
      • 同種異系
    • 運用規模別
      • 前臨床
      • 臨床
      • 商業
    • 調達別
      • 社内
      • 受託製造
    • 用途別
      • 腫瘍
      • 心血管疾患
      • 整形外科疾患
      • その他
    • エンドユーザー別
      • 医薬・バイオテクノロジー企業
      • 学術・調査機関
      • その他
    • 企業別
    • 地域別
  • 製品市場マップ

第7章 北米市場の分析・予測

  • 市場規模・予測
  • 市場シェア・予測
    • 治療法別
    • 細胞区分別
    • 運用規模別
    • 調達別
    • 用途別
    • エンドユーザー別
    • 国別

第8章 欧州市場の分析・予測

  • 市場規模・予測
  • 市場シェア・予測
    • 治療法別
    • 細胞区分別
    • 運用規模別
    • 調達別
    • 用途別
    • エンドユーザー別
    • 国別

第9章 アジア太平洋市場の分析・予測

  • 市場規模・予測
  • 市場シェア・予測
    • 治療法別
    • 細胞区分別
    • 運用規模別
    • 調達別
    • 用途別
    • エンドユーザー別
    • 国別

第10章 南米市場の分析・予測

  • 市場規模・予測
  • 市場シェア・予測
    • 治療法別
    • 細胞区分別
    • 運用規模別
    • 調達別
    • 用途別
    • エンドユーザー別
    • 国別

第11章 中東・アフリカ市場の分析・予測

  • 市場規模・予測
  • 市場シェア・予測
    • 治療法別
    • 細胞区分別
    • 運用規模別
    • 調達別
    • 用途別
    • エンドユーザー別
    • 国別

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向

第14章 特許分析

第15章 臨床試験

第16章 競合情勢

  • 競合の見通し
  • 企業プロファイル
    • KBI Biopharma, Inc.
    • Waisman Biomanufacturing
    • Cell and Gene Therapy Catapult
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • Catalent Inc.
    • Lonza Group
    • Oxford Biomedica Plc
    • Fujifilm Cellular Dynamics, Inc.
    • Wuxi Apptec
    • Charles River Laboratories International, Inc.
    • The Discovery Labs LLC
    • ABL, Inc.
    • BioCentriq
    • Commercializing Living Therapies

第17章 戦略的提言

第16章 当社について&免責事項

目次
Product Code: 7729

Global cell therapy manufacturing market is projected to grow in the forecast period, 2022-2026 with an impressive CAGR. The market growth can be attributed to rapid growth of biopharmaceutical industries, all over the globe. The development of the advancing therapies and transforming paradigm of several life threatening diseases is driving the growth of the global cell therapy manufacturing market in the upcoming five years. The ongoing COVID-19 pandemic has played a significant role in growth of the global cell therapy manufacturing market. Healthcare industry was involved with the extensive research and technological advancements that leads to the advanced medicine and treatment facilities for the patients. The urgent need for effective therapies as well as vaccine against the infection supported the exponential growth in the market in the past two years. The market is expected to sustain similar growth in future five years on the same factor. Although the research is consistently growing, the expertise in the sector is limited and the lack of specialized infrastructure to produce cell therapies and various product development may cause a mild restraint on the future growth of the market.

The global cell therapy manufacturing market is segmented on the basis of therapy, source of cell, scale of operation, source, application, end user, competitional landscape, and regional distribution. Based on basis of therapy, the market is further bifurcated into T-cell therapies, dendritic cell therapies, tumor cell therapies, and stem cell therapies. Stem cell therapy is anticipated to hold the largest shares of the market and dominate the segment in the next five years on the account of rising research and development in the area. Stem cells therapy are utilized for the cures of various chronic diseases and the consistent efforts to provide the best available treatment to the patients. Additionally, growing number of ongoing clinical trials and increased stem cell therapy products in the market is aiding the growth of the global cell therapy manufacturing market in the upcoming five years. Rising FDA approvals, and dedicated biopharma companies for the consistent evolution of the cell therapies are also substantiating the growth of the global cell therapy manufacturing market in the next five years.

Holding the major shares of the global cell therapy manufacturing market are KBI Biopharma, Inc., Waisman Biomanufacturing, Cell and Gene Therapy Catapult, Thermo Fisher Scientific, Inc., Merck KGaA, Catalent Inc., Lonza Group, Oxford Biomedica Plc, Fujifilm Cellular Dynamics, Inc., Wuxi Apptec, Charles River Laboratories International, Inc., The Discovery Labs LLC, ABL, Inc., BioCentriq, Commercializing Living Therapies, among others. Market players are actively involved in the research and technological development in the medical applications of the cell therapy and related developments. The advanced technology has made it possible for the healthcare industry to provide excellent healthcare services through cell therapy manufacturing. Further advancement would aid the market value and brand establishment in the future five years. New market players may focus on the research and development to provide options that satisfies the consumer demand as well as benefits the market players in building their brand value. Other competitive strategies include mergers & acquisitions and new product developments.

Years considered for this report:

Historical Years: 2016 - 2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022 - 2026

Objective of the Study:

  • To analyze the historical growth of the market size of global cell therapy manufacturing market from 2016 to 2019.
  • To estimate and forecast the market size of global cell therapy manufacturing market from 2020 to 2026 and growth rate until 2026.
  • To classify and forecast global cell therapy manufacturing market based on therapy, source of cell, scale of operation, source, application, end user, competitional landscape, and regional distribution.
  • To identify dominant region or segment in the global cell therapy manufacturing market.
  • To identify drivers and challenges for global cell therapy manufacturing market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global cell therapy manufacturing market.
  • To identify and analyze the profile of leading players operating in global cell therapy manufacturing market.
  • To identify key sustainable strategies adopted by market players in global cell therapy manufacturing market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and distributors across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of global cell therapy manufacturing market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Manufacturers, end users, and other stakeholders
  • Distributors and suppliers of products and other stakeholders
  • Organizations, forums, and alliances related to cell therapy manufacturing
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global cell therapy manufacturing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Cell Therapy Manufacturing Market, By Therapy:

T-Cell Therapies

Dendritic Cell Therapies

Tumor Cell Therapies

Stem Cell Therapies

  • Global Cell Therapy Manufacturing Market, By Source of Cell:

Autologous

Allogenic

  • Global Cell Therapy Manufacturing Market, By Scale of Operation:

Preclinical

Clinical

Commercial

  • Global Cell Therapy Manufacturing Market, By Source:

In-House

Contract Manufacturing

  • Global Cell Therapy Manufacturing Market, By Application:

Oncology

Cardiovascular Diseases

Orthopedic Diseases

Others

  • Global Cell Therapy Manufacturing Market, By End User:

Pharmaceutical & Biotechnology Companies

Academic & Research Institutes

Others

  • Global Cell Therapy Manufacturing Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global cell therapy manufacturing market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Cell Therapy Manufacturing Market

4. Voice of Customer

  • 4.1. Popularly used cells for Cell Therapy Manufacturing
  • 4.2. Commonly Used Cell Therapies
  • 4.3. Brand Awareness

5. Executive Summary

6. Global Cell Therapy Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
    • 6.2.2. By Source of Cell (Autologous v/s Allogenic)
    • 6.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
    • 6.2.4. By Source (In-House v/s Contract Manufacturing)
    • 6.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
    • 6.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
    • 6.2.7. By Company (2020)
    • 6.2.8. By Region
  • 6.3. Product Market Map

7. North America Cell Therapy Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Source of Cell
    • 7.2.3. By Scale of Operation
    • 7.2.4. By Source
    • 7.2.5. By Application
    • 7.2.6. By End User
    • 7.2.7. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Cell Therapy Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Source of Cell
        • 7.3.1.2.3. By Scale of Operation
        • 7.3.1.2.4. By Source
        • 7.3.1.2.5. By Application
        • 7.3.1.2.6. By End User
    • 7.3.2. Mexico Cell Therapy Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Source of Cell
        • 7.3.2.2.3. By Scale of Operation
        • 7.3.2.2.4. By Source
        • 7.3.2.2.5. By Application
        • 7.3.2.2.6. By End User
    • 7.3.3. Canada Cell Therapy Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Source of Cell
        • 7.3.3.2.3. By Scale of Operation
        • 7.3.3.2.4. By Source
        • 7.3.3.2.5. By Application
        • 7.3.3.2.6. By End User

8. Europe Cell Therapy Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Source of Cell
    • 8.2.3. By Scale of Operation
    • 8.2.4. By Source
    • 8.2.5. By Application
    • 8.2.6. By End User
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Cell Therapy Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Source of Cell
        • 8.3.1.2.3. By Scale of Operation
        • 8.3.1.2.4. By Source
        • 8.3.1.2.5. By Application
        • 8.3.1.2.6. By End User
    • 8.3.2. Germany Cell Therapy Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Source of Cell
        • 8.3.2.2.3. By Scale of Operation
        • 8.3.2.2.4. By Source
        • 8.3.2.2.5. By Application
        • 8.3.2.2.6. By End User
    • 8.3.3. United Kingdom Cell Therapy Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Source of Cell
        • 8.3.3.2.3. By Scale of Operation
        • 8.3.3.2.4. By Source
        • 8.3.3.2.5. By Application
        • 8.3.3.2.6. By End User
    • 8.3.4. Italy Cell Therapy Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Source of Cell
        • 8.3.4.2.3. By Scale of Operation
        • 8.3.4.2.4. By Source
        • 8.3.4.2.5. By Application
        • 8.3.4.2.6. By End User
    • 8.3.5. Spain Cell Therapy Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Source of Cell
        • 8.3.5.2.3. By Scale of Operation
        • 8.3.5.2.4. By Source
        • 8.3.5.2.5. By Application
        • 8.3.5.2.6. By End User

9. Asia-Pacific Cell Therapy Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Source of Cell
    • 9.2.3. By Scale of Operation
    • 9.2.4. By Source
    • 9.2.5. By Application
    • 9.2.6. By End User
    • 9.2.7. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Cell Therapy Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Source of Cell
        • 9.3.1.2.3. By Scale of Operation
        • 9.3.1.2.4. By Source
        • 9.3.1.2.5. By Application
        • 9.3.1.2.6. By End User
    • 9.3.2. India Cell Therapy Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Source of Cell
        • 9.3.2.2.3. By Scale of Operation
        • 9.3.2.2.4. By Source
        • 9.3.2.2.5. By Application
        • 9.3.2.2.6. By End User
    • 9.3.3. South Korea Cell Therapy Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Source of Cell
        • 9.3.3.2.3. By Scale of Operation
        • 9.3.3.2.4. By Source
        • 9.3.3.2.5. By Application
        • 9.3.3.2.6. By End User
    • 9.3.4. Japan Cell Therapy Manufacturing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapy
        • 9.3.4.2.2. By Source of Cell
        • 9.3.4.2.3. By Scale of Operation
        • 9.3.4.2.4. By Source
        • 9.3.4.2.5. By Application
        • 9.3.4.2.6. By End User
    • 9.3.5. Australia Cell Therapy Manufacturing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapy
        • 9.3.5.2.2. By Source of Cell
        • 9.3.5.2.3. By Scale of Operation
        • 9.3.5.2.4. By Source
        • 9.3.5.2.5. By Application
        • 9.3.5.2.6. By End User

10. South America Cell Therapy Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Source of Cell
    • 10.2.3. By Scale of Operation
    • 10.2.4. By Source
    • 10.2.5. By Application
    • 10.2.6. By End User
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cell Therapy Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Source of Cell
        • 10.3.1.2.3. By Scale of Operation
        • 10.3.1.2.4. By Source
        • 10.3.1.2.5. By Application
        • 10.3.1.2.6. By End User
    • 10.3.2. Argentina Cell Therapy Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Source of Cell
        • 10.3.2.2.3. By Scale of Operation
        • 10.3.2.2.4. By Source
        • 10.3.2.2.5. By Application
        • 10.3.2.2.6. By End User
    • 10.3.3. Colombia Cell Therapy Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Source of Cell
        • 10.3.3.2.3. By Scale of Operation
        • 10.3.3.2.4. By Source
        • 10.3.3.2.5. By Application
        • 10.3.3.2.6. By End User

11. Middle East and Africa Cell Therapy Manufacturing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy
    • 11.2.2. By Source of Cell
    • 11.2.3. By Scale of Operation
    • 11.2.4. By Source
    • 11.2.5. By Application
    • 11.2.6. By End User
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Cell Therapy Manufacturing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapy
        • 11.3.1.2.2. By Source of Cell
        • 11.3.1.2.3. By Scale of Operation
        • 11.3.1.2.4. By Source
        • 11.3.1.2.5. By Application
        • 11.3.1.2.6. By End User
    • 11.3.2. Saudi Arabia Cell Therapy Manufacturing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapy
        • 11.3.2.2.2. By Source of Cell
        • 11.3.2.2.3. By Scale of Operation
        • 11.3.2.2.4. By Source
        • 11.3.2.2.5. By Application
        • 11.3.2.2.6. By End User
    • 11.3.3. UAE Cell Therapy Manufacturing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapy
        • 11.3.3.2.2. By Source of Cell
        • 11.3.3.2.3. By Scale of Operation
        • 11.3.3.2.4. By Source
        • 11.3.3.2.5. By Application
        • 11.3.3.2.6. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Patent Analysis

15. Clinical Trials

16. Competitive Landscape

  • 16.1. Competition Outlook
  • 16.2. Company Profiles (SWOT Analysis of Top 5 Players Profiled)
    • 16.2.1. KBI Biopharma, Inc.
    • 16.2.2. Waisman Biomanufacturing
    • 16.2.3. Cell and Gene Therapy Catapult
    • 16.2.4. Thermo Fisher Scientific, Inc.
    • 16.2.5. Merck KGaA
    • 16.2.6. Catalent Inc.
    • 16.2.7. Lonza Group
    • 16.2.8. Oxford Biomedica Plc
    • 16.2.9. Fujifilm Cellular Dynamics, Inc.
    • 16.2.10. Wuxi Apptec
    • 16.2.11. Charles River Laboratories International, Inc.
    • 16.2.12. The Discovery Labs LLC
    • 16.2.13. ABL, Inc.
    • 16.2.14. BioCentriq
    • 16.2.15. Commercializing Living Therapies

17. Strategic Recommendations

18. About Us & Disclaimer